HLHilal A. Lashuel

Hilal A. Lashuel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hilal A. Lashuel has a total of 737 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Middle East collaborative for undiagnosed diseases

    by Omer S. Alkhnbashi, Hamad Ali, Almundher Al-Maawali, Naif A. M. Almontashiri, Uğur Özbek, Maha S. Zaki, Mouhammed Ali Ajlouny, Issa Abu-Dayyeh, Rami Abdel-Rahim Mahfouz, Abdullah M. Baghfar, et al.


  • Open Access

    A Site-Specific Organometallic Approach for Installing Tyrosine Phosphorylation Mimics to Decipher the Role of Phosphorylation in α-Synuclein Aggregation and Seeding

    by Shaswati Mandal, Xiaoxi Lin, Anastasia V. Gemelli, Manjeet Singh, Anne-Laure Mahul-Mellier, Yllza Jasiqi, Bouchra Bouri, Muhammad Jbara, Hilal A. Lashuel

    Several studies have identified phosphorylation of α-synuclein (aSyn) at multiple tyrosine residues (Y39, Y125, Y133, and Y136) within Lewy bodies (LB), which are the pathological hallmarks of Parkinson’s disease (PD). However, understanding the specific role of phosphorylation at each site, or how multiple phosphorylation sites interact, has been challenging. Herein, we present an efficient method that leverages an organometallic Pd-complex to site-specifically attach phosphomimetic groups via Cys-arylation, closely mimicking natural phosphorylation. Using this approach, we successfully incorporated native-like tyrosine phosphorylation mimics into cysteine-containing proteins like synthetic transcription factor Max and recombinant aSyn, in good yields. To demonstrate the method’s versatility, we created a focused library of mono-, di-, and triphosphorylated aSyn analogues. This development enabled, for the first time, the investigation of the effect of site-specific phosphorylation at multiple C-terminal tyrosine residues on aSyn fibrillization and aggregation. Our results show that monophosphorylation at any of the C-terminal sites has little effect on aggregation, while di- and triphosphorylation slows down the process, extending the lag phase compared to wild-type aSyn. Additionally, phosphorylation at Y39 reduces the seeding activity of aSyn fibrils by almost 2–4-fold in both mammalian and neuronal models of synuclein pathology. Overall, our strategy provides a rapid, selective, and scalable way to introduce aromatic PTMs, producing homogeneous protein libraries essential for mechanistic studies, biomarker development, and exploring the therapeutic potential of targeting aSyn-phosphorylation for PD and related disorders.

  • Open Access

    Modeling Parkinson’s pathology in human iPSC dopaminergic neurons uncovers key mechanisms of Lewy body formation and heterogeneity

    by Anne-Laure Mahul-Mellier, Lukas van Den Heuvel, Maxime Teixeira, Manel L. N. Boussouf, Gaspard Oudinot, Amélie Thonet, Davide Speri, Yllza Jasiqi, Christina Ulrich, Razan Sheta, et al.

    The aggregation of alpha-synuclein (aSyn) into intraneuronal inclusions of heterogeneous morphology, known as Lewy bodies (LBs), is a defining hallmark of Parkinson’s disease (PD); yet, our understanding of the mechanisms underpinning their formation and heterogeneity remains incomplete. Here, we present a human isogenic induced pluripotent stem cell–derived dopaminergic neuron (iDA) model that faithfully recapitulates the diverse biochemical, morphological, and ultrastructural features of LB neuropathology. The iDA model accurately reproduces the temporal relationships between neuritic and cell-body aSyn pathology and recapitulates the proteome, posttranslational modifications, and morphological diversity of aSyn aggregates found in human PD tissue. Moreover, our work provides critical insight into how different pathways to aSyn fibrillization and the complex interaction between aSyn fibrils and membranous organelles shape the morphological diversity of LB-like inclusions. This model represents a versatile platform to investigate the mechanisms of pathology formation, maturation, and neuronal dysfunction and to develop diagnostics and therapeutics that account for the diversity of aSyn pathology in PD and related synucleinopathies.


  • Cracking the code of native amyloid fibrils: advances and next steps to enable pathology-informed therapeutic and diagnostic

    by Hilal A. Lashuel

    Cryo-electron microscopy studies on amyloid fibrils formed by different proteins and isolated from the brains of persons with neurodegenerative diseases have consistently shown that their core structure is distinct from that of fibrils formed by the same proteins in cell-free systems. Attempts to replicate brain-derived amyloid fibrils in vitro have thus far fallen short of faithfully reproducing their structure, post-translational modifications and pathological properties. Whether this discrepancy is a major contributing factor to the poor clinical translation of antiamyloid therapies and diagnostics remains uncertain, partially because the structure of amyloid fibrils formed in the commonly used preclinical models remains unknown. This article presents (1) an overview of recent advances and progress toward reproducing disease-relevant pathological aggregates in vitro and in preclinical models of neurodegenerative diseases; (2) an experimental strategy to determine the structure of fibrils from these models; and (3) recommendations for optimizing their use to bridge the translational gap and support the development of more effective therapies. Establishing that the process of fibrillization and inclusion formation can be faithfully recapitulated in preclinical models is also crucial for enhancing their translational relevance and to guide the development of disease-relevant diagnostics and therapeutics. Until native fibrils can be produced at scale, the choice of which type of fibril preparation to use should be guided by the specific research question and intended application as different applications may warrant different levels of biochemical and structural similarity to disease-derived fibrils.


  • A genomics health strategy for the Arabian Gulf

    by Hamad Ali, Barrak Alahmad, Abdullah Alibrahim, Dana Marafi, Hind Alsharhan, Salman Al Sabah, Almundher Al-Maawali, Khalid A. Fakhro, Hilal A. Lashuel, Fowzan S. Alkuraya, et al.

  • Open Access

    Recapitulating Parkinson’s pathology in human iPSC dopaminergic neurons reveals new mechanistic insights into Lewy body formation and heterogeneity

    by Anne-Laure Mahul-Mellier, Lukas van Den Heuvel, Maxime Teixeira, Manel L. N. Boussouf, Gaspard Oudinot, Amélie Thonet, Davide Speri, Yllza Jasiqi, Christina Ulrich, Razan Sheta, et al.

    The accumulation of alpha-synuclein (aSyn) into intraneuronal inclusions of heterogeneous morphology, known as Lewy bodies (LB), is one of the defining diagnostic features of Parkinson’s disease (PD); yet, our understanding of the mechanisms underpinning their formation and heterogeneity remains incomplete. Here, we present a human isogenic iPSC-derived dopaminergic neuron (iDA) model that faithfully recapitulates the diverse biochemical, morphological, and ultrastructural features of LB neuropathology in PD. Unlike other iDA seeding models, our model does not rely on aSyn overexpression, mutations, or genetic engineering, making it a more physiologically relevant system for studying PD. We demonstrate that the iDA model accurately reproduces the temporal relationships between neuritic and cell-body aSyn pathology, recapitulating the full biochemical spectrum, post-translational modifications (PTM), and morphological diversity of aSyn aggregates found in human PD tissue. Moreover, our work provides critical insight into how different pathways to aSyn fibrillization and the complex interaction between aSyn fibrils and membranous organelles influence the morphological diversity of LB-like inclusions. This model represents a versatile platform for investigating the mechanisms of pathology formation, maturation, and neuronal dysfunction, as well as supporting the development of diagnostics that capture the diversity of aSyn pathology in PD and related synucleinopathies.


  • Open Access

    Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation

    by Anne-Laure Mahul-Mellier, Melek Firat Altay, Niran Maharjan, Nadine Ait-Bouziad, Anass Chiki, Somanath Jagannath, Galina Limorenko, Salvatore Novello, Jonathan Ricci, Yllza Jasiqi, et al.

    Alpha-synuclein (aSyn) post-translational modifications (PTM), especially phosphorylation at serine 129 and C-terminal truncations, are highly enriched in Lewy bodies (LB), Lewy neurites, and other pathological aggregates in Parkinson’s disease and synucleinopathies. However, the precise role of these PTM in pathology formation, neurodegeneration, and pathology spreading remains unclear. Here, we systematically investigated the role of post-fibrillization C-terminal aSyn truncations in regulating uptake, processing, seeding, and LB-like inclusion formation using a neuronal seeding model that recapitulates LB formation and neurodegeneration. We show that C-terminal cleavage of aSyn fibrils occurs rapidly post exogenous fibril internalization and during intracellular LB-like inclusion formation. Blocking cleavage of internalized fibrils does not affect seeding, but inhibiting enzymes such as calpains 1 and 2 alters LB-like inclusion formation. We show that C-terminal truncations, along with other PTMs, regulate fibril interactome remodeling, shortening, lateral association, and packing. These findings reveal distinct roles of C-terminal truncations at different aggregation stages on the pathway to LB formation, highlighting the need for consideration of stage‑specific strategies to target aSyn proteolytic cleavages.


  • Open Access

    A Microfluidic Platform for Whole-Membrane Integrity Profiling in Live Neuronal Cells

    by Till Ryser, Ata Krichene, Nicolò Marchi, Felix Rodriguez Espinal, Anne-Laure Mahul-Mellier, Hilal A. Lashuel, Carlotta Guiducci

    Structural and functional compromise of the cellular membrane are central mechanisms in the pathogenesis of numerous diseases, including neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. However, existing techniques for assessing membrane integrity often lack the ability to provide dynamic, whole-cell measurements and are limited to localized damage detection or population-level analysis. There is a growing need for methods capable of monitoring membrane integrity over time at the single-cell level and across the entire membrane surface. In this study, we present a microfluidic platform for real-time, label-free assessment of membrane integrity by analyzing dielectric properties. We apply this system to investigate how different aggregated forms of α-Synuclein (aSyn), a protein that plays a central role in the pathogenesis of Parkinson’s disease and disrupts neuronal membranes. Our platform integrates electrokinetic microdevices with 3D microelectrodes and imaging, enabling continuous analysis of up to 30 live neuronal cells per hour under flow. By measuring electrorotation responses, we quantify changes in plasma membrane capacitance in response to monomeric, oligomeric, and fibrillar aSyn. This approach allows direct, time-resolved comparison of membrane-disruptive effects across different aSyn conformations with single-cell resolution and whole-membrane sensitivity.

  • Integrating the genome and exposome for precision health in Kuwait

    by Hamad Ali, Barrak Alahmad, Faisal H. Al-Refaei, Ahmad Abou Tayoun, Hilal A. Lashuel, Salman Al Sabah, Fahd Al-Mulla


  • Open Access

    Nanoplasmonic Infrared Microarray Sensor Enabling Structural Protein Biomarker‐Based Drug Screening for Neurodegenerative Diseases

    by Deepthy Kavungal, Enzo Morro, Senthil T Kumar, Berkay Dagli, Hilal A Lashuel, Hatice Altug

    The misfolding of proteins from native monomers into β‐sheet‐rich fibrils via oligomers is a key hallmark of neurodegenerative diseases (NDDs). Identifying and screening drugs that inhibit protein aggregation for early disease intervention remains challenging due to the limitations of existing methods. This work introduces a novel nanoplasmonic infrared microarray sensor for label‐free and high‐throughput drug screening based on structural protein biomarkers in NDDs. The sensor employs 2D arrays of nanoplasmonic units compartmentalized in micropatterned polymeric microwells for high‐throughput protein sensing and secondary structural analysis. The flexibility of the on‐chip integrated microarray sensor is showcased through ultra‐compact 48, 96, and 384 microwell designs, enabling detection from as low as 2 nL of sample volume and with a 100 pg/mL sensitivity in under a minute of in situ measurement. The drug screening capability is validated by assessing multiple drug compounds in a multiplexed manner for their inhibiting effect on aSyn aggregation, an important NDDs protein biomarker. The microarray sensor successfully quantified the secondary structural changes in drug‐treated protein samples, detecting both oligomers and fibrils, which the conventional fluorescence‐based assays failed to do. Thus, the nanoplasmonic microarray sensor is a promising advancement in the NDDs and pharmaceutical research for drug screening.